On September 16, 2024, ZyVersa Therapeutics, Inc. announced the entry into an At-The-Market (ATM) Sales Agreement with A.G.P./Alliance Global Partners. Under the agreement, ZyVersa may offer and sell shares of its common stock up to an aggregate offering price of $1,397,396. The sales will be conducted at prevailing market prices or as agreed with the Agent, who will receive a 3% commission on gross proceeds from any shares sold. The ATM Agreement allows for sales by any method deemed to be an 'at the market offering' as defined by law, with the amount and timing of sales determined by ZyVersa. There is no obligation for either party to sell or buy any shares, and no minimum offering amount is...Show More

On September 16, 2024, ZyVersa Therapeutics, Inc. announced the entry into an At-The-Market (ATM) Sales Agreement with A.G.P./Alliance Global Partners. Under the agreement, ZyVersa may offer and sell shares of its common stock up to an aggregate offering price of $1,397,396. The sales will be conducted at prevailing market prices or as agreed with the Agent, who will receive a 3% commission on gross proceeds from any shares sold. The ATM Agreement allows for sales by any method deemed to be an 'at the market offering' as defined by law, with the amount and timing of sales determined by ZyVersa. There is no obligation for either party to sell or buy any shares, and no minimum offering amount is required. The proceeds from any sales are intended for working capital and general corporate purposes, including administrative and R&D expenses. The offering of shares will be made under ZyVersa's shelf registration statement and prospectus filed with the SEC. The ATM Agreement includes customary representations, warranties, and covenants by ZyVersa, and it will terminate upon reaching the aggregate offering amount or earlier if conditions permit. The agreement also includes indemnification obligations for the Agent against certain liabilities.